Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

The hantavirus outbreak may no longer be confined to the luxury Dutch cruise ship MV Hondius, with health officials now assessing the possibility of wider exposure. Officials at the US Centers for Disease Control and Prevention (CDC) said that although no cases have been reported in the US so far, the agency is monitoring 41 people for possible exposure.

The 41 includes the 18 people evacuated from the hantavirus-hit ship from Spain’s Canary Islands.

Notably, of the 18 passengers evacuated, two were carried in the plane's biocontainment units out of an abundance of caution — one who tested positive and another considered a suspected case. They were quarantined at a special facility in Nebraska. The remaining 16 are being quarantined in Omaha and Atlanta.

Speaking to CNN from a biocontainment unit at the University of Nebraska Medical Center in Omaha, Dr. Stephen Kornfeld of Oregon said he “feels wonderful” and is not experiencing symptoms.

Spanish officials confirmed that after initially testing positive for hantavirus, Dr. Kornfeld has since tested negative twice for the disease, meaning no Americans currently have the illness, Forbes reported.

CDC Monitoring More People

However, an additional 16 people are being monitored by the CDC.

The new individuals were not on the cruise ship but were passengers on an April 25 flight to Johannesburg and were exposed to someone known to have been infected, said Dr. David Fitter, who is leading the CDC response to the outbreak, according to The New York Times.

Also read: Shocking Study Finds Andes Hantavirus Could Linger In Semen For Years, Pose Transmission Risk

Seven other passengers from the cruise ship had disembarked on April 24 in St. Helena, an island in the Atlantic Ocean, returned to the US on commercial flights, and are being monitored by state health departments.

As of May 14, there were no confirmed hantavirus cases in the United States, Dr. Fitter said.

“Our job is to ensure that we are monitoring and in contact with anybody that might have been on the flight this person had taken,” Dr. Fitter told reporters. The agency is “monitoring all Americans that potentially would have been exposed, whether in the US or abroad, and we have been in contact with them,” he said.

Hantavirus Outbreak: 11 Cases And 3 Deaths Reported

According to the World Health Organization (WHO), 11 people have been affected by the rat-borne virus so far, of whom three have died.

A Dutch couple is believed to have first been exposed to the virus while visiting a birdwatching site in Argentina.

The WHO has confirmed that the Andes strain of hantavirus — the only strain known to spread from person to person — is behind the outbreak.

While all passengers onboard the cruise have been taken care of by health authorities, the virus’ long incubation period remains a serious concern. This means that even asymptomatic individuals could potentially become infectious 6-8 weeks later.

WHO Guidelines On Hantavirus Exposure

The WHO recommends that people exposed to hantavirus should be:

• Monitored actively at a specified quarantine facility
• Monitored at home for 42 days from the last exposure

The UK is witnessing yet another outbreak of meningitis, with one college student dead and two others infected in Berkshire, according to the UK Health Security Agency (UKHSA).

According to the agency, close contacts of those affected are being offered antibiotics as a precautionary measure.

Also Read: Why Rebranding PCOS As PMOS Could Mark A New Era In Women’s Health

While stressing that the risk to the wider public remains low, the UKHSA confirmed that one case has been identified as Meningitis B (MenB), while further testing is ongoing.

The latest infections come after a small number of meningitis B cases were reported in the Weymouth region in April, followed by a major outbreak in Kent in March that affected more than 30 people and led to the deaths of a sixth-form pupil and a university student.

What’s The Meningitis Situation In Reading?

The young person who died attended The Henley College, according to a local GP surgery.

Authorities are reportedly sharing information about the infection with students and parents at affected schools. The other two cases are believed to be linked to schools in the Reading area. But the officials are yet to disclose the exact link.

Health officials said close contacts of the infected individuals are being offered antibiotics as a precaution.

Read More: Hantavirus Outbreak: Critically Ill French Patient On Artificial Lung Support

GP surgery, the Hart Surgery, based in Henley-on-Thames, stated that it was in contact with the UKHSA due to the college’s location, adding that the agency was “actively contacting those who may be at risk due to a close association with the student involved.”

However, it said anyone whom the UKHSA has not contacted does not require treatment, and students and staff can continue attending the sixth-form college as usual.

“The number of confirmed cases is very low, so there are currently no plans for a local emergency meningitis vaccination programme,” it added.

Also read: UK Reports Meningitis Outbreak Among School Children: All You Need To Know

What Is Meningitis?

Meningitis is a serious medical condition that affects the protective membranes covering the brain and spinal cord, known as the meninges. Fever is often considered one of the classic symptoms, although it may not always be present.

Understanding the symptoms, causes, and treatment options is important for early diagnosis and timely medical care.

“Anyone can get meningitis, and around 300 to 400 cases of meningococcal disease are diagnosed in England every year. It is most common in babies, young children, teenagers, and young adults," said Dr Rachel Mearkle, a consultant in health protection at the UKHSA.

“It needs to be treated quickly, so it is important to know the signs and symptoms. They can appear in any order and may not all be present, so seek rapid medical attention if there is ever any concern," she added.

The expert noted that "meningococcal meningitis requires very close contact to spread, and large outbreaks such as the one recently seen in Kent are thankfully rare."

“Meningococcal disease does not spread easily, and the risk to the wider public remains low.”

Symptoms Of Meningitis

Health officials urged the public to remain alert to the warning signs of meningococcal meningitis. Common symptoms include:

• Rash
• Headache
• Neck stiffness
• Fever
• Drowsiness
• Nausea or vomiting
• Increased sensitivity to light

“If the disease is suspected, immediate medical attention should be sought, as it can progress rapidly,” the officials said. While antibiotics provide the quickest short-term protection, vaccines offer longer-term protection.

Pancreatic cancer has long been one of the toughest challenges in oncology. With a five-year survival rate hovering around 13 per cent and recurrence rates approaching 80 per cent after treatment, the odds have historically been stacked against patients.

However, an experimental drug called daraxonrasib, developed by the US-based late-stage clinical oncology company Revolution Medicines, has shown promise in improving survival rates in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

“For patients with metastatic pancreatic cancer, new treatment options are urgently needed to increase survival time and improve quality of life,” said Brian M. Wolpin, professor of medicine at Harvard Medical School, and principal investigator for the trial.

Wolpin noted that the study “indicates that daraxonrasib provides a clear and highly meaningful step forward for patients with pancreatic cancer who have experienced progression on prior treatment, typically chemotherapy.”

What Is Daraxonrasib?

Daraxonrasib is a once-daily oral pill that demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with standard intravenous chemotherapy.

Daraxonrasib, described as a multi-selective inhibitor of RAS(ON) proteins, is the first investigational drug in a new class of RAS inhibitors designed to target a broad spectrum of cancer-causing RAS mutations.

In the clinical trial, daraxonrasib showed a median overall survival of 13.2 months, compared with 6.7 months for chemotherapy.

The drug was generally well tolerated and showed a manageable safety profile, with no new safety concerns identified.

Daraxonrasib works by blocking KRAS signalling proteins that drive tumor growth.

Pancreatic cancer is considered one of the most RAS-addicted cancers, with more than 90 per cent of patients carrying tumours driven by RAS protein mutations.

Also read: Former US Senator Ben Sasse Opens Up About Battle With Terminal Stage 4 Pancreatic Cancer

Daraxonrasib: The Clinical Trial

The controlled Phase 3 clinical trial evaluated daraxonrasib in patients with previously treated metastatic PDAC.

The trial included patients with pancreatic tumours carrying a wide range of RAS variants, as well as patients without identified RAS mutations.

The results showed that daraxonrasib significantly improved overall survival in patients with previously treated metastatic pancreatic cancer.

Similar RAS-targeting drugs are now being developed by other companies for pancreatic, lung, and colon cancers.

“It’s the beginning, not the end,” said Elizabeth Jaffee in comments to The New York Times.

What are the side effects?

According to the company, “Daraxonrasib was generally well tolerated, with a manageable safety profile and with no new safety signals.”

Prior studies with daraxonrasib have shown that rash is the most common side effect, with mouth sores, diarrhea, nausea, and vomiting also common.

Also read: India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi

FDA fast-tracks Daraxonrasib

Based on the first interim analysis, all progression-free survival and overall survival results are now considered final.

Revolution Medicines said it plans to submit the data to global regulators, including the US Food and Drug Administration (FDA), as part of a future New Drug Application under a Commissioner’s National Priority Voucher.

The findings are also expected to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

What Is Pancreatic Cancer? Know The Warning Signs

Pancreatic cancer typically begins in the ducts of the organ and can rapidly spread from there to the rest of the organ. Early-stage pancreatic tumors do not show up on imaging tests, making this version of the disease difficult to diagnose until it infects other organs.

The prevention and early detection remain vital.

Experts warn that pancreatic cancer often masquerades as common ailments, delaying diagnosis. Here are some early symptoms that should never be ignored:

• Abdominal or back pain that worsens over time or eases when leaning forward.
• Unexplained weight loss without changes in diet or exercise.
• Jaundice, including yellowing of the eyes and skin, sometimes with intense itching.
• Changes to urine or stool, such as dark urine or pale, greasy stools.
• New-onset diabetes without obvious risk factors.
• Persistent fatigue unrelated to poor sleep or lifestyle